Publications by the researcher in collaboration with Manuel Barreiro de Acosta (33)

2024

  1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833

  2. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  3. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

    Digestive Diseases

  4. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758

  5. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

2023

  1. Is Occupation a Risk Factor for Developing Inflammatory Bowel Disease? A Case–Control Study

    Crohn's and Colitis 360, Vol. 5, Núm. 4

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  3. Managing ulcerative colitis after surgery

    Frontiers in Medicine

  4. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort

    Scandinavian Journal of Gastroenterology

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  3. Radon exposure and inflammatory bowel disease in a radon prone area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 405-409

  4. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 805-818

  5. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 737-741

  6. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

    Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83

  7. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 1, pp. 10-15

2021

  1. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

    Therapeutic Advances in Gastroenterology, Vol. 14

  2. Role of quality of life as endpoint for inflammatory bowel disease treatment

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 13

  3. ¿Qué debe conocer el cirujano del diagnóstico y tratamiento médico de la enfermedad de Crohn intestinal?

    Prácticum en coloproctología de la ACPE: estrategias y técnicas para la práctica diaria (Ergon), pp. 343-353

2020

  1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596